Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada. more
Time Frame | ONCY | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.24% | -3.39% | 0.2% |
1-Month Return | -22.51% | -1.92% | 2.72% |
3-Month Return | -19.58% | -10.54% | 7.31% |
6-Month Return | -23.66% | -4.47% | 10.44% |
1-Year Return | -39.29% | 4.06% | 27.53% |
3-Year Return | -48.26% | 0.94% | 30.88% |
5-Year Return | -57.17% | 36.67% | 89.21% |
10-Year Return | -84.39% | 102.87% | 199.95% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 485.57K | 446.19K | 452.06K | 392.00K | 403.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":91.89,"profit":true},{"date":"2021-12-31","value":93.1,"profit":true},{"date":"2022-12-31","value":80.73,"profit":true},{"date":"2023-12-31","value":82.99,"profit":true}] |
Gross Profit | (485.57K) | (446.19K) | (452.06K) | (392.00K) | (403.00K) | [{"date":"2019-12-31","value":-48557400,"profit":false},{"date":"2020-12-31","value":-44618700,"profit":false},{"date":"2021-12-31","value":-45206500,"profit":false},{"date":"2022-12-31","value":-39200000,"profit":false},{"date":"2023-12-31","value":-40300000,"profit":false}] |
Gross Margin | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 20.69M | 25.46M | 26.23M | 26.92M | 33.79M | [{"date":"2019-12-31","value":61.24,"profit":true},{"date":"2020-12-31","value":75.34,"profit":true},{"date":"2021-12-31","value":77.64,"profit":true},{"date":"2022-12-31","value":79.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (20.69M) | (25.46M) | (26.23M) | (28.57M) | (33.79M) | [{"date":"2019-12-31","value":-2069335700,"profit":false},{"date":"2020-12-31","value":-2545900600,"profit":false},{"date":"2021-12-31","value":-2623494500,"profit":false},{"date":"2022-12-31","value":-2856900000,"profit":false},{"date":"2023-12-31","value":-3379100000,"profit":false}] |
Total Non-Operating Income/Expense | (12.25M) | 3.08M | 78.56K | 2.70M | 7.29M | [{"date":"2019-12-31","value":-168.11,"profit":false},{"date":"2020-12-31","value":42.2,"profit":true},{"date":"2021-12-31","value":1.08,"profit":true},{"date":"2022-12-31","value":37.07,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (33.12M) | (22.51M) | (26.25M) | (24.75M) | (27.66M) | [{"date":"2019-12-31","value":-3312288800,"profit":false},{"date":"2020-12-31","value":-2250505700,"profit":false},{"date":"2021-12-31","value":-2625485200,"profit":false},{"date":"2022-12-31","value":-2475100000,"profit":false},{"date":"2023-12-31","value":-2765500000,"profit":false}] |
Income Taxes | 12.43M | (2.95M) | 49.43K | 84.00K | 97.00K | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-23.77,"profit":false},{"date":"2021-12-31","value":0.4,"profit":true},{"date":"2022-12-31","value":0.68,"profit":true},{"date":"2023-12-31","value":0.78,"profit":true}] |
Income After Taxes | (45.55M) | (19.55M) | (26.30M) | (24.84M) | (27.75M) | [{"date":"2019-12-31","value":-4555241900,"profit":false},{"date":"2020-12-31","value":-1955110800,"profit":false},{"date":"2021-12-31","value":-2630427900,"profit":false},{"date":"2022-12-31","value":-2483500000,"profit":false},{"date":"2023-12-31","value":-2775200000,"profit":false}] |
Income From Continuous Operations | (33.12M) | (22.51M) | (26.30M) | (24.84M) | (32.36M) | [{"date":"2019-12-31","value":-3312288800,"profit":false},{"date":"2020-12-31","value":-2250505700,"profit":false},{"date":"2021-12-31","value":-2630427900,"profit":false},{"date":"2022-12-31","value":-2483500000,"profit":false},{"date":"2023-12-31","value":-3235700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (45.55M) | (19.55M) | (26.30M) | (24.84M) | (27.75M) | [{"date":"2019-12-31","value":-4555241900,"profit":false},{"date":"2020-12-31","value":-1955110800,"profit":false},{"date":"2021-12-31","value":-2630427900,"profit":false},{"date":"2022-12-31","value":-2483500000,"profit":false},{"date":"2023-12-31","value":-2775200000,"profit":false}] |
EPS (Diluted) | (0.93) | (0.43) | (0.49) | (0.44) | (0.41) | [{"date":"2019-12-31","value":-93,"profit":false},{"date":"2020-12-31","value":-43,"profit":false},{"date":"2021-12-31","value":-49,"profit":false},{"date":"2022-12-31","value":-44,"profit":false},{"date":"2023-12-31","value":-41,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ONCY | |
---|---|
Cash Ratio | 2.56 |
Current Ratio | 2.99 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ONCY | |
---|---|
ROA (LTM) | -71.33% |
ROE (LTM) | -138.22% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ONCY | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.63 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.37 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ONCY | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 0.00 |
P/B | 9.34 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | NM |
Oncolytics Biotech Inc (ONCY) share price today is $0.768
Yes, Indians can buy shares of Oncolytics Biotech Inc (ONCY) on Vested. To buy Oncolytics Biotech Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ONCY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Oncolytics Biotech Inc (ONCY) via the Vested app. You can start investing in Oncolytics Biotech Inc (ONCY) with a minimum investment of $1.
You can invest in shares of Oncolytics Biotech Inc (ONCY) via Vested in three simple steps:
The 52-week high price of Oncolytics Biotech Inc (ONCY) is $1.53. The 52-week low price of Oncolytics Biotech Inc (ONCY) is $0.75.
The price-to-earnings (P/E) ratio of Oncolytics Biotech Inc (ONCY) is
The price-to-book (P/B) ratio of Oncolytics Biotech Inc (ONCY) is 9.34
The dividend yield of Oncolytics Biotech Inc (ONCY) is 0.00%
The market capitalization of Oncolytics Biotech Inc (ONCY) is $59.74M
The stock symbol (or ticker) of Oncolytics Biotech Inc is ONCY